Get the Stockscreener App
68.20
1.37%
-0.95
After Hours:
68.30
0.10
+0.15%
Corcept Therapeutics Inc stock is traded at $68.20, with a volume of 853.03K.
It is down -1.37% in the last 24 hours and down -6.86% over the past month.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.
See More
Previous Close:
$69.15
Open:
$69.15
24h Volume:
853.03K
Relative Volume:
0.65
Market Cap:
$7.23B
Revenue:
$628.56M
Net Income/Loss:
$141.82M
P/E Ratio:
54.13
EPS:
1.26
Net Cash Flow:
$142.60M
1W Performance:
-1.27%
1M Performance:
-6.86%
6M Performance:
+10.84%
1Y Performance:
+86.70%
1-Day Range:
$67.75
$69.44
1-Week Range:
$67.44
$70.44
52-Week Range:
$32.33
$117.33
Corcept Therapeutics Inc Stock (CORT) Company Profile
Name
Corcept Therapeutics Inc
Sector
Industry
Phone
650.688.8803
Address
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
Compare CORT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CORT
Corcept Therapeutics Inc
|
68.20 | 7.33B | 628.56M | 141.82M | 142.60M | 1.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.41 | 118.34B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.14 | 60.31B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
330.55 | 42.35B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
598.79 | 36.43B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
305.74 | 31.87B | 3.81B | -644.79M | -669.77M | -6.24 |
Corcept Therapeutics Inc Stock (CORT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-06-23 | Upgrade | Truist | Hold → Buy |
| Apr-11-23 | Initiated | SVB Securities | Market Perform |
| Apr-04-23 | Initiated | Piper Sandler | Overweight |
| Feb-15-23 | Downgrade | Jefferies | Buy → Hold |
| Aug-01-22 | Downgrade | Truist | Buy → Hold |
| Jul-27-22 | Upgrade | Jefferies | Hold → Buy |
| Jun-27-22 | Resumed | Canaccord Genuity | Buy |
| Feb-02-22 | Initiated | Canaccord Genuity | Buy |
| Jan-28-22 | Initiated | Truist | Buy |
| Aug-05-20 | Downgrade | Jefferies | Buy → Hold |
| Sep-24-19 | Initiated | Jefferies | Buy |
| Sep-06-19 | Initiated | H.C. Wainwright | Buy |
| Feb-04-19 | Downgrade | B. Riley FBR | Buy → Neutral |
| Aug-10-18 | Reiterated | Stifel | Hold |
| May-31-18 | Downgrade | Stifel | Buy → Hold |
| Mar-09-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Aug-31-17 | Initiated | Stifel | Buy |
| Feb-02-17 | Initiated | Ladenburg Thalmann | Buy |
| Apr-21-15 | Initiated | FBR Capital | Outperform |
| Jan-13-14 | Downgrade | Stifel | Buy → Hold |
| Aug-09-13 | Downgrade | Janney | Buy → Neutral |
| Aug-09-13 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Feb-21-12 | Reiterated | JMP Securities | Mkt Outperform |
| Jan-06-10 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jul-17-08 | Initiated | Rodman & Renshaw | Mkt Outperform |
| Jun-21-07 | Upgrade | Punk, Ziegel & Co | Mkt Perform → Accumulate |
View All
Corcept Therapeutics Inc Stock (CORT) Latest News
Corcept Therapeutics' Q2 Earnings: A Critical Inflection Point for Growth and Innovation - AInvest
What To Expect From Corcept’s (CORT) Q2 Earnings - FinancialContent
Technical Charts Suggest Momentum Shift in Corcept Therapeutics IncorporatedSmart Allocation Stock Pick Insights Gaining Interest - metal.it
Published on: 2025-07-28 23:53:14 - metal.it
When is Corcept Therapeutics Incorporated stock expected to show significant growthCapitalize on momentum-driven investment opportunities - jammulinksnews.com
Why Corcept Therapeutics Incorporated stock attracts strong analyst attention Daily Equity Signal Strength Summary Report - metal.it
What are the technical indicators suggesting about Corcept Therapeutics IncorporatedAchieve rapid capital gains with smart investing - jammulinksnews.com
H.C. Wainwright Remains Bullish on Corcept Therapeutics Incorporated (CORT) - Yahoo Finance
Why is Corcept Therapeutics Incorporated stock attracting strong analyst attentionFree Investment Community - jammulinksnews.com
Corcept Therapeutics Advances Pipeline Fueling Growth With Controlled Risk - Yahoo Finance
10 Most Profitable Biotech Stocks to Invest in Now - Insider Monkey
Corcept Therapeutics’ ALS Study: A Potential Game-Changer? - TipRanks
Should I buy Corcept Therapeutics Incorporated stock before earningsHigh-octane financial growth - jammulinksnews.com
Is Corcept Therapeutics Incorporated a good long term investmentConsistent high-performance stocks - PrintWeekIndia
What drives Corcept Therapeutics Incorporated stock priceUnbelievable profit margins - PrintWeekIndia
What analysts say about Corcept Therapeutics Incorporated stockExceptional financial outcomes - Autocar Professional
Is Corcept Therapeutics Incorporated stock overhyped or has real potentialFree Market Dynamics Reports - jammulinksnews.com
Corcept (CORT) Advances Ovarian Cancer Therapy with FDA Filing for Relacorilant - Yahoo.co
Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call - Business Wire
Corcept Advances Cancer Drug as Analysts Back Strong Growth Prospects - Yahoo Finance
Corcept Therapeutics Incorporated Stock Analysis and ForecastConsistently outstanding ROI - Autocar Professional
Corcept Therapeutics (NASDAQ:CORT): A High-Conviction Buy in the Biopharma Sector Amid EPS Growth and Strategic Momentum - AInvest
Here's Why We Think Corcept Therapeutics (NASDAQ:CORT) Is Well Worth Watching - Yahoo Finance
Here's How Much You Would Have Made Owning Corcept Therapeutics Stock In The Last 5 Years - Benzinga
Corcept Therapeutics Incorporated (NASDAQ:CORT) is largely controlled by institutional shareholders who own 70% of the company - simplywall.st
agilon health, LifeStance Health Group, The Pennant Group, Corcept, and Amphastar Pharmaceuticals Shares Plummet, What You Need To Know - Yahoo Finance
FDA approval sought of relacorilant for platinum-resistant ovarian cancer - Rare Cancer News
M&T Bank Corp Sells 3,530 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
Corcept Therapeutics Incorporated (NASDAQ:CORT) Director Daniel N. Swisher, Jr. Sells 2,200 Shares of Stock - Defense World
Corcept Seeks FDA Approval for Relacorilant in Ovarian Cancer - Yahoo Finance
Why Corcept Therapeutics Incorporated stock attracts strong analyst attentionShort Term Profit Focus - Newser
How rare disease-focused Corcept Therapeutics expanded into cancerSan Francisco Business Times - The Business Journals
Corcept seeks FDA approval for ovarian cancer treatment (CORT) - Seeking Alpha
Corcept Therapeutics' Relacorilant NDA Submission: A Breakthrough in Ovarian Cancer and a Strategic Pivot to Oncology - AInvest
Corcept Therapeutics Submits New Drug Application to FDA - TipRanks
Corcept Therapeutics Files New Drug Application for Treatment of Platinum-Resistant Ovarian Cancer - MarketScreener
Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer - Business Wire
Corcept Therapeutics Inc Stock (CORT) Financials Data
Revenue
Net Income
Cash Flow
EPS
10.28%
2.59%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):